Effect of Octreotide on Intestinal Motility and Bacterial Overgrowth in Scleroderma

Soudah, Hani C.; Hasler, William L.; Owyang, Chung

doi:10.1056/nejm199111213252102

Cited by 373 publications

(195 citation statements)

References 33 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Appropriate caloric support must be provided by IV infusion. Erythromycin, somatostatin and neostigmine can be used to promote transit and decrease the duration of acute episodes [61][62][63] .…”

Section: Treatment Of the Acute Phasementioning

confidence: 99%

Chronic intestinal pseudo-obstruction

Antonucci¹,

Fronzoni²,

Cogliandro³

et al. 2008

WJG

190

238

View full text Add to dashboard Cite

Section: Treatment Of the Acute Phasementioning

confidence: 99%

Chronic intestinal pseudo-obstruction

Antonucci¹,

Fronzoni²,

Cogliandro³

et al. 2008

WJG

190

238

View full text Add to dashboard Cite

“…A role for motilin in the decreased intestinal motility in SSc remains purely speculative. It was observed recently that the somatostatin analog octreotide stimulates intestinal motility independently of the effects of motilin in patients with pseudoobstruction and bacterial overgrowth due to scleroderma (5). This indicates that other peptides may also be involved in SSc.…”

Section: Ma0 and Npymentioning

confidence: 99%

“…There is evidence of a defect in neurotransmitter release (3). Recent studies have shown that regulatory peptides act as neurotransmitters, and are involved in gastrointestinal motility, secretion, and absorption (4)(5)(6).…”

Section: Peptides Inmentioning

confidence: 99%

“…The C-terminal fragment of NPY is sufficient to elicit the prejunctional effects, i.e., release of norepinephrine, whereas the whole molecule is required to evoke the postjunctional effects, i.e., contraction of vascular smooth muscle (17). Further characterization of this neuroendocrine system, which influences gastrointestinal motility, absorption, and secretion, may add valuable information about the gastrointestinal dysfunction in SSc, especially since effective treatment with peptide analogs is available (5).…”

Section: Ma0 and Npymentioning

confidence: 99%

See 1 more Smart Citation

Gastrointestinal regulatory peptides in systemic sclerosis

Åkesson

Ekman

1993

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Gastrointestinal involvement commonly occurs in systemic sclerosis (SSc), but its pathogenesis is not well understood. Since there is evidence of a defect in neurotransmitter release, we were interested in examining the relationship between gastrointestinal dysfunction and plasma concentrations of gastrointestinal regulatory peptides in patients with SSc. We studied 43 consecutive patients, 18 with diffuse and 25 with limited cutaneous disease.Methods. Levels of corticotropin-releasing hormone (CRH), gastrin, motilin, neuropeptide Y (NPY), and peptide YY (PYY) were determined by radioimmunoassay and high-performance liquid chromatography (HPLC).Results. Plasma concentrations of CRH, motilin, NPY, and PYY were significantly increased among SSc patients compared with healthy control subjects, and HPLC-characterization of motilin, NPY, and PYY showed a different pattern of fragments. No correlation was found between esophageal hypomotility and the concentration of peptide. Acid output did not correlate with gastrin levels, but was more often increased in patients with increased CRH and NPY values. Fat

show abstract

“…(21) Several studies have shown an association between dysfunction of intestinal motility and bacterial proliferation. (23)(24)(25)(26) In an experimental study Nieuwenhuijs et al compared infusion of morphine with placebo. Significant changes of intestinal motility were recorded in the group receiving morphine.…”

Section: Bacterial Translocationmentioning

confidence: 99%